Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

The biopharmaceutical company Array BioPharma has formed a collaboration agreement with Biogen Idec  for the discovery and development of inhibitors targeting a kinase for treating autoimmune disorders.  Under the terms of the...

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibodies for treating cancer and autoimmune diseases, and Takeda Pharmaceutical Company Limited, have formed an option agreement for...

Pfizer Inc. has appointed Morris J. Birnbaum, M.D., Ph.D., as chief scientific officer for cardiovascular and metabolic disease research. He will report directly to Rod MacKenzie, Ph.D., group senior vice president and head of PharmaTherapeutics...

Aduro BioTech, Inc., a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotech, Inc. an exclusive, worldwide license to certain product candidates specifically engineered for treating prostate cancer based on...

The Commonwealth of Puerto Rico and Actavis plc have announced an approximately $48 million investment to improve and expand the company's manufacturing operations in Puerto Rico.The new investment includes the development of a solid dosage...

Actavis plc has filed an abbreviated new drug application (ANDA) with FDA seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg, a a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza, which is indicated as an...

Sanofi and Eli Lilly and Company have formed an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction. Under...

GlaxoSmithKline plc reported that is has been informed by the UK's Serious Fraud Office (SFO), an independent government agency, that the SFO has opened a formal criminal investigation into the group's commercial practices....